Mood disorder

EQS-News: Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Sunday, January 22, 2023

New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Thursday, January 5, 2023

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder

Retrieved on: 
Thursday, December 1, 2022

Ulotaront, which is also being evaluated in Phase 3 clinical development for the treatment of schizophrenia, is the first TAAR1 agonist to be studied as an adjunctive therapy in the treatment of MDD.

Key Points: 
  • Ulotaront, which is also being evaluated in Phase 3 clinical development for the treatment of schizophrenia, is the first TAAR1 agonist to be studied as an adjunctive therapy in the treatment of MDD.
  • Ulotaront was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in 2019.
  • Its also the first TAAR1 agonist to enter into a Phase 2/3 clinical study as an adjunctive therapy for MDD.
  • Major depressive disorder is a chronic debilitating disease characterized by symptoms that last at least two weeks causing significant functional impairment.

Neuromodulation Devices Markets, 2029 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022

The "Neuromodulation Devices Global Market- Forecast To 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neuromodulation Devices Global Market- Forecast To 2029" report has been added to ResearchAndMarkets.com's offering.
  • The treatment delivered by neuromodulation devices brings about life-changing transformation in patients who fail to get better by traditional approaches.
  • Based on the product, the neuromodulation global market is segmented into invasive neuromodulation devices and non-invasive neuromodulation devices.
  • Among these, invasive neuromodulation devices segment accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2029.

Elysian Wellness: Veteran Owned Ketamine Clinic Celebrates 1-Year Anniversary

Retrieved on: 
Friday, November 11, 2022

Elysian enters its second year of business serving the Hampton Roads community by offering ketamine therapy for those suffering from depression, anxiety, PTSD, suicidal ideations, and chronic pain.

Key Points: 
  • Elysian enters its second year of business serving the Hampton Roads community by offering ketamine therapy for those suffering from depression, anxiety, PTSD, suicidal ideations, and chronic pain.
  • Elysian Wellness is the only practice in Hampton Roads that is run exclusively by Navy Veterans.
  • Our personal experience with fellow uniformed service members and their families inspired us to open Elysian Wellness.
  • Ketamine therapy has proven effective at Elysian Wellness; we have provided relief to more than 80 % of our patients.

EQS-News: Reset Pharmaceuticals announces appointment of neuroscience industry leader Lisa Deschamps to the Board of Directors

Retrieved on: 
Thursday, November 3, 2022

Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.

Key Points: 
  • Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.
  • Before this, she was Worldwide Business Head, Neuroscience at Novartis, where she was responsible for the development and commercialization of the neuroscience portfolio.
  • She has been involved in more than a dozen successful product approvals and launches in many therapeutic areas, including in neuroscience.
  • We are very happy to welcome Lisa to the Board, said Philip Taub, Chair of the Board of Reset Pharma.

Reset Pharmaceuticals announces appointment of neuroscience industry leader Lisa Deschamps to the Board of Directors

Retrieved on: 
Wednesday, November 2, 2022

Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.

Key Points: 
  • Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.
  • Before this, she was Worldwide Business Head, Neuroscience at Novartis, where she was responsible for the development and commercialization of the neuroscience portfolio.
  • She has been involved in more than a dozen successful product approvals and launches in many therapeutic areas, including in neuroscience.
  • We are very happy to welcome Lisa to the Board, said Philip Taub, Chair of the Board of Reset Pharma.

Clinical Research by Salem Anaesthesia Pain Clinic, Surrey, Canada, Shows That Clonidine is Better Than Zopiclone for Insomnia Treatment

Retrieved on: 
Wednesday, November 2, 2022

SURREY, British Columbia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- A clinical research study has shown that Clonidine is better than Zopiclone for insomnia treatment in chronic pain patients.

Key Points: 
  • SURREY, British Columbia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- A clinical research study has shown that Clonidine is better than Zopiclone for insomnia treatment in chronic pain patients.
  • The critically acclaimed research was led and authored by Dr. Olu Bamgbade at the Salem Anaesthesia Pain Clinic in Surrey, British Columbia, Canada.
  • Dr. Olu Bamgbade is the director of the Salem Anaesthesia Pain Clinic, a specialist pain clinic and research center( https://salempainclinic.net/ ).
  • Based in Surrey, British Columbia, Canada, Salem Anaesthesia Pain Clinic is aspecialist pain clinic and research center that provides multimodal pain management, interventional pain treatment, substance misuse therapy, insomnia treatment and preoperative optimization therapy.

COVID-19 was one of the costliest medical conditions in 2021, with the highest claim reaching $1.75 million, Sun Life claims data shows

Retrieved on: 
Tuesday, June 21, 2022

WELLESLEY, Mass., June 21, 2022 /PRNewswire/ -- Sun Life U.S. has released its 10th annual report on high-cost medical claims, analyzing its stop-loss claims data and medical trends from 2018 – 2021. COVID-19 rose to a top 10 costliest condition in 2021, with the highest-cost COVID-19 claim reaching $1.75 million. Other categories of medical claims, including cancer and mental health claims, showed increases as well. The report reviewed nearly 50,000 Sun Life member claims from more than 2,800 self-funded employer clients around the country, providing research and data indicative of U.S. healthcare trends. The rise in claims over the study period are the result of increases in underlying medical claims cost as well as changes to Sun Life's book of covered business.

Key Points: 
  • COVID-19 rose to a top 10 costliest condition in 2021, with the highest-cost COVID-19 claim reaching $1.75 million.
  • Other categories of medical claims, including cancer and mental health claims, showed increases as well.
  • Sun Life also provides members with health advisory and care navigation services through its Health Navigator solution, powered by PinnacleCare.
  • COVID-19 claims that were severe enough to breach stop-loss deductibles averaged $231,300, with the highest claim at $1.75 million.

Pandemic-related stressors in pregnant women may impact their babies before they’re born

Retrieved on: 
Thursday, May 26, 2022

This is what a study published in Communications Medicine suggests after following more than 200 pregnant women.

Key Points: 
  • This is what a study published in Communications Medicine suggests after following more than 200 pregnant women.
  • The psychosocial impact of COVID-19 on fetal brain development remains vastly understudied.
  • This study builds upon previous work from the Developing Brain Institute led by Limperopoulos, which discovered that anxiety in pregnant women appears to affect the brain development of their babies.
  • As a non-profit, Children's National Hospital relies on generous donors to help ensure that every child receives the care they need.